![]() Several weeks, successfully completing its first manufacturing lot at increased scale and beginning its second manufacturing lot at increased scale. The Company has made significant progress with TEPEZZA drug product supply over the last Regarding the increased scale manufacturing process of TEPEZZA. The length of the TEPEZZA supply disruption will depend on whether future manufacturing slots are successfully completed as well as decisions by the U.S. The Company anticipates that thisĭrug supply shortage could last through the first quarter. 17, 2020 the Company expects a short-term disruption in TEPEZZA supply as a result of government-mandated COVID-19 vaccine production orders related to Operation Warp Speed that dramatically restricted capacity available for TEPEZZA at its drug product contract manufacturer, Catalent. Horizon will report its final fourth quarter and full-yearĪs previously announced on Dec. These preliminary financial results are unaudited and subject to adjustment. 31, 2020 were $2.08 billion and gross leverage was less than 1.1 times. KRYSTEXXA full-year 2020 net sales exceeded $400 million, with double-digit sequential growth in the fourthĬash and cash equivalents at Dec. TEPEZZA full-year 2020 net sales exceeded $800 million, with double-digit sequential growth in the fourth ![]() Treatment of Thyroid Eye Disease (TED), and KRYSTEXXA, its biologic for the treatment of uncontrolled gout (chronic gout refractory to conventional therapy), as well as continued growth of its Rare Disease Business Unit. The outperformance was driven by strong net sales from its two key growth drivers, TEPEZZA, its biologic for the $940 million exceeding the high end of this guidance range represents year-over-year growth of more than 95 percent and an adjusted EBITDA margin expansion of more than 700 basis points compared to 2019. $2.14 billion exceeding the high end of this guidance range represents year-over-year growth of more than 65 percent.įull-year 2020 adjusted EBITDA exceeded the high end of the Companys guidance range of $920 million to Submit the resultant data to the FDA by the end of this month.įull-Year 2020 Preliminary Financial Results (unaudited)įull-year 2020 net sales exceeded the high end of the Companys guidance range of $2.12 billion to Additionally, we successfully completed the first increased scale TEPEZZA lot and we are on track to ![]() We deliveredĮxceptional shareholder value while expanding our pipeline, with six programs expected to begin this year, including two new KRYSTEXXA programs. Net sales and adjusted EBITDA guidance, driven by the significant outperformance of TEPEZZA and the strong second-half performance of KRYSTEXXA, said Tim Walbert, chairman, president and chief executive officer, Horizon. ∺mid the most challenging environment we have ever faced, we had a record year of performance, exceeding our full-year 2020 11, 2021 Horizon Therapeutics plc (Nasdaq: HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and Morgan Healthcare Conference on Tuesday, Jan. ![]() ![]() Company to present at 39 th Annual J.P. TEPEZZA ® (teprotumumab-trbw) Supply and New KRYSTEXXA ® (pegloticase injection) Trials Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceedingįull-Year 2020 Net Sales and Adjusted EBITDA Guidance Provides Update on ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |